#VisualAbstract: Encorafenib, Cetuximab, and mFOLFOX6 Improves Survival in BRAF-Mutated Colorectal Cancer
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: colorectal cancer
Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer
1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the ...
#VisualAbstract: Invitation to Fecal Immunochemical Test is Noninferior to Colonoscopy Screening in Colorectal Cancer Mortality
Click here to read this study in the Lancet. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Nivolumab plus ipilimumab improves progression-free survival in metastatic colorectal cancer
1. Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events ...
Fluorouracil, leucovorin and irinotecan plus panitumumab for the treatment of metastatic colorectal cancer
1. An intermittent strategy with fluorouracil, leucovorin and irinotecan (FOLFIRI) plus panitumumab (PAN) following induction was feasible, showed reduced toxicity ...
Grading carcinoembryonic antigen levels can enhance prognostic stratification in colorectal cancer
1. Higher CEA levels in patients with colorectal cancer are indicative of aggressive tumour phenotypes and survival Evidence Rating Level: ...
Liver transplantation plus chemotherapy improves survival in patients with unresectable colorectal liver metastases
1. 5-year survival was significantly greater in the liver transplantation plus chemotherapy group compared to chemotherapy alone. 2. Serious adverse ...
Neoadjuvant chemotherapy does not appear to significantly improve disease-free survival in patients with locally advanced colon cancer
1. When compared to upfront surgery, neoadjuvant chemotherapy using mFOLFOX or CAPOX did not appear to significantly improve 3-year disease-free ...
#VisualAbstract: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to ...
#VisualAbstract: Preoperative Treatment of Locally Advanced Rectal Cancer
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...